GT
BIO icon

Glenmede Trust’s Bio-Rad Laboratories Class A BIO Stock Holding History

Glenmede Trust’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-833
Closed -$274K – 1381
2024
Q4 		$274K Sell
833
-217
-21% -$73.7K ﹤0.01% 1131
2024
Q3 		$351K Buy
+1,050
New +$333K ﹤0.01% 1047
2020
Q4 		– Sell
-32
Closed -$15K – 1329
2020
Q3 		$15K Buy
32
+5
+19% +$2.53K ﹤0.01% 1710
2020
Q2 		$11K Sell
27
-2,373
-99% -$1.05M ﹤0.01% 1815
2020
Q1 		$888K Hold
2,400
– – ﹤0.01% 764
2019
Q4 		$888K Buy
+2,400
New +$846K ﹤0.01% 764
2017
Q4 		– Sell
-554
Closed -$122K – 2674
2017
Q3 		$122K Sell
554
-752
-58% -$169K ﹤0.01% 1369
2017
Q2 		$260K Hold
1,306
– – ﹤0.01% 1124
2017
Q1 		$260K Hold
1,306
– – ﹤0.01% 1124
2016
Q4 		$237K Hold
1,306
– – ﹤0.01% 1160
2016
Q3 		$213K Hold
1,306
– – ﹤0.01% 1175
2016
Q2 		$186K Hold
1,306
– – ﹤0.01% 1198
2016
Q1 		$177K Hold
1,306
– – ﹤0.01% 1193
2015
Q4 		$181K Hold
1,306
– – ﹤0.01% 1198
2015
Q3 		$174K Hold
1,306
– – ﹤0.01% 1210
2015
Q2 		$195K Sell
1,306
-269
-17% -$38.5K ﹤0.01% 1227
2015
Q1 		$212K Hold
1,575
– – ﹤0.01% 1226
2014
Q4 		$189K Sell
1,575
-21
-1% -$2.42K ﹤0.01% 1321
2014
Q3 		$180K Buy
1,596
+21
+1% +$2.49K ﹤0.01% 1210
2014
Q2 		$188K Hold
1,575
– – ﹤0.01% 1192
2014
Q1 		$201K Hold
1,575
– – ﹤0.01% 1172
2013
Q4 		$194K Hold
1,575
– – ﹤0.01% 1165
2013
Q3 		$185K Hold
1,575
– – ﹤0.01% 1153
2013
Q2 		$176K Buy
+1,575
New +$185K ﹤0.01% 1123

Other funds holding BIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Glenmede Trust's BIO Position: Q1 2025 in Review

Glenmede Trust sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2025, closing a stake of 833 shares — an estimated $274K sold.

Glenmede Trust first reported a position in BIO in Q2 2013 and held it in 24 quarters. The position peaked at $888K in Q1 2020. 436 funds tracked by Wall St. Rank hold BIO as of Q1 2025.

  • Glenmede Trust reported no remaining Bio-Rad Laboratories Class A position as of Q1 2025 after selling out during the quarter.
  • Glenmede Trust sold 833 Bio-Rad Laboratories Class A shares in Q1 2025, an estimated $274K.
  • Glenmede Trust first reported a position in Bio-Rad Laboratories Class A in Q2 2013 and held it in 24 quarters.
  • Glenmede Trust's Bio-Rad Laboratories Class A position peaked at $888K in Q1 2020.
  • 436 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2025.

Based on Glenmede Trust's 13F filing for Q1 2025, filed 15 May 2025.